22.05.2017 Views

Review of Pharmacology - 9E (2015)

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Endocrinology<br />

I 131 can be used for the treatment <strong>of</strong> hyperthyroidism but response is slow (maximum response<br />

may take 3 months). Thyroid peroxidase inhibitors are administered to make the patient<br />

euthyroid. After a gap <strong>of</strong> 5 days (after stopping anti-thyroid drugs), radioactive iodine<br />

is given and thyroid peroxidase inhibitor treatment is resumed till the effect <strong>of</strong> I 131 starts.<br />

Radioactive iodine therapy is primarily indicated for patients older than 35 years, those with<br />

heart disease and in the presence <strong>of</strong> other contra-indications <strong>of</strong> surgery. These drugs are<br />

not suitable for young children and in the pregnancy. Another disadvantage <strong>of</strong> radioactive<br />

iodine is that if hypothyroidism develops, it is permanent (requiring life long T 4<br />

therapy).<br />

Coexisting ophthalmopathy is a relative contra-indication.<br />

5. Drugs inhibiting the peripheral conversion <strong>of</strong> T 4<br />

to T 3<br />

Propanolol and propylthiouracil inhibits the generation <strong>of</strong> more active T 3<br />

from T 4<br />

by inhibiting<br />

5’-deiodinase. These drugs therefore, can be used in the treatment <strong>of</strong> hyperthyroidism.<br />

Amiodarone also inhibit this enzyme and thus can result in hypothyroidism.<br />

6. Adjuvant Drugs<br />

• β-blockers (propanolol, esmolol, atenolol) antagonize the sympathetic effects <strong>of</strong><br />

thyrotoxicosis like tremors, tachycardia, palpitations and anxiety.<br />

• Calcium channel blockers like diltiazem can also be used for this purpose.<br />

• Steroids (i.v. methylprednisolone) are used for Graves’s opthalmopathy. Latter can<br />

be aggravated by I 131 and thiazolidinediones (like pioglitazone and rosiglitazone).<br />

INSULIN AND ORAL HYPOGLYCEMIC AGENTS<br />

Diabetes mellitus (DM) is diagnosed when fasting blood glucose exceeds 126 mg/dl<br />

(or postprandial > 200 mg/dl or HbA 1c<br />

> 6.5g%). Type I DM (IDDM) is treated only by<br />

insulin whereas in the treatment <strong>of</strong> type II DM (NIDDM), orally active drugs are tried first<br />

in uncomplicated cases. Insulin is used in all the patients <strong>of</strong> type I diabetes mellitus and<br />

in the patients <strong>of</strong> type II diabetes who are not controlled with oral hypoglycemic agents<br />

(OHA), in pregnancy, to tide over stressful situations (like surgery) and in complications (like<br />

ketoacidosis and hyperosmolar coma).<br />

Insulin<br />

It was discovered by Banting and Best in 1921. It consists <strong>of</strong> 51 amino acids arranged in two<br />

chains; A (21 amino acids) and B (30 amino acids). Pork insulin differs from human insulin<br />

by one amino acid only whereas beef insulin has a difference <strong>of</strong> three amino acids. Half<br />

life <strong>of</strong> insulin in plasma is about 5-6 minutes. Glucose is the main stimulus for the release <strong>of</strong><br />

insulin from the β cells <strong>of</strong> pancreas. Glucose stimulates GLUT-2 and inhibits ATP sensitive K +<br />

channels; factors that are responsible for the depolarization <strong>of</strong> β cells and release <strong>of</strong> insulin. α 2<br />

receptor stimulation inhibits insulin secretion whereas β 2<br />

agonists and vagal stimulation<br />

enhances insulin release. Somatostatin inhibits whereas glucagon stimulates the release <strong>of</strong> insulin.<br />

Adrenergic system regulates insulin release via α 2<br />

(decreases) and β 2<br />

(increases) receptors.<br />

Actions<br />

α 2<br />

receptor stimulation inhibits<br />

insulin secretion whereas β 2<br />

agonists and vagal stimulation<br />

enhances insulin release.<br />

General Endocrinology <strong>Pharmacology</strong><br />

1. It decreases blood glucose by<br />

• Stimulating the entry <strong>of</strong> glucose in muscle and fat (by increasing the synthesis<br />

<strong>of</strong> GLUT 4).<br />

• Inhibiting glycogenolysis (by inhibiting phosphorylase) and gluconeogenesis<br />

(by inhibiting phosphoenol pyruvate carboxykinase). These processes are<br />

inhibited at lower concentration <strong>of</strong> insulin.<br />

• Increasing glycolysis (by stimulation <strong>of</strong> glucokinase) and glycogenesis (by<br />

stimulating glycogen synthase). These require more concentration <strong>of</strong> insulin.<br />

2. It inhibits lipolysis and thus favors triglyceride deposition.<br />

3. It increases the synthesis and inhibits the breakdown <strong>of</strong> proteins.<br />

Advantage <strong>of</strong> rapid acting<br />

insulins (lispro etc) is that<br />

their duration <strong>of</strong> action remain<br />

constant (~ 4 hours) irrespective<br />

<strong>of</strong> dose. This contrasts with all<br />

other insulins (including regular)<br />

where duration <strong>of</strong> action is<br />

prolonged with increase in dose<br />

241<br />

https://kat.cr/user/Blink99/

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!